Archive for January 2023

Good morning, Boston. Here are the five things you need to know in Boston business news to start your workday, plus mobile sports betting, Norman Rockwell, Amplify Latinx, National Save the Eagles Day and why employees may be looking for the exit. Read More

The global pharmaceutical giant GSK is significantly expanding its presence in Cambridge’s Alewife neighborhood, with an eye on bringing together R&D staff to focus on RNA technology. Read More

While Biogen’s new CEO says he isn’t planning any "radical left turns," he does see some ways the company could tap into new markets, including immunology and rare diseases. Read More

Employees are most likely to leave their job if their employer doesn’t stand by their values — even more than if they don’t receive a raise they felt like they deserved, according to a new Boston Business Journal/Seven Letter poll. Read More

There are several things that need to happen before the new Alzheimer’s drug from Biogen and Eisai gets into the hands of patients. And, unlike with their first Alzheimer’s drug, Aduhelm, Eisai is taking the charge on this one — leaving Biogen in a bit of a wait-and-see position. Read More

A new poll shows that clear majority of likely Massachusetts voters want the Legislature and Gov. Maura Healey to leave untouched the 1986 tax law that triggered nearly $3 billion in mandatory rebates last year. Read More

Cambridge, Mass – The Forsyth Institute is pleased Read More

MGH researchers have designed mathematical model that can predict how frequently people should receive Covid-19 boosters based on whether or not they have suppressed immune responses. Read More

The Cambridge gene-editing company is laying off 20% of its workforce as it cuts drug programs geared toward retinal diseases and solid tumors. Read More

Voyager Therapeutics Inc., the gene therapy startup led by erstwhile Biogen Inc. executive Al Sandrock, has a new deal with a San Diego biotech that’s worth up to $4.2 billion. Read More